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Dear Editor,  
 
Barbiturate is a potent substance which forms a quintessential part of the NDPS Act. The 
substance is categorized under the psychoactive groups of drugs and is essentially a drug that 
possesses both hypnotic and sedative properties. The precursor for barbiturate is barbituric acid 
which is a condensation product of malonic acid and urea. However, barbituric acid itself is not 
a centrally acting depressant. Diethylbarbituric acid (Veronal) is the first ever barbiturate with 
hypnotic properties that was used as early as 1903 (Hadjihambi et al., 2020). The drug induced 
sleep both in human and animals. The substance was also called as barbital. Later in the year 
1912, a second barbiturate drug, phenobarbitone was introduced into clinical practice which 
had both sedative and hypnotic properties. The phenomenal success of both these drugs an-
nounced the beginning of the barbiturate era. Their influence as the pre-eminent sedative-hyp-
notic agents was felt for over half a century. Although several so-called non-barbiturate drugs 
attempted to displace the barbiturates from their pinnacle from time to time, it was not until 
1961 when a substance named chlordiazepoxide was introduced into the market that their po-
sition was seriously challenged (Velle et al., 2021). Several earlier studies have reported the 
characteristic features and the severity of the barbiturate withdrawal syndrome. In cases of mild 
withdrawal syndrome, symptoms like apprehension, hyperexcitability, mild tremors, loss of 
appetite and piloerection were observed. An intermediate withdrawal syndrome exhibited tight-
ness in the muscles, extreme tremors, sudden loss of body weight, altered motor activity, ex-
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cessive nausea, and vomiting (Sharpe et al., 2020). The hallmarks of a severe withdrawal syn-
drome are convulsions, delirium or hallucination and hyperthermia or unusually high fever. The 
severity of withdrawal syndrome has been shown to depend on the frequency of drug admin-
istration and the duration of action of the drug. We review recent research on the role of barbi-
turates in brain disorders in this letter (Table 1). 
 
Table 1: Recent study on the role of barbiturates in brain disorders 
Brain disorder Key findings Reference 
Epilepsy Brandt et al. reported several key advantages of bumepamine 
over bumetanide in targeting the nervous system. Some of 
these are; the potential of bumepamine to regulate diuresis, 
ability to render the drug more permeable and causing in-
creased efficacy of the drug which in turn enhances the antiepi-
leptic potential of phenobarbital. 
Brandt et al., 
2018 
Klein et al. showed that both carbamazepine and phenytoin 
produced a far lesser therapeutic effect against focal noncon-
vulsive seizures, whereas valproate and levetiracetam re-
vealed a moderate activity and phenobarbital and diazepam 
demonstrated marked anti-seizure effects. In addition, all AEDs 
are shown to restrain generalized convulsive seizures.  
Klein et al., 
2015 
The antiepileptic activity of phenobarbital was enhanced when 
compared with bumetanide. Observations in the rat kindling 
model, namely BUM5 (N,N-dimethylaminoethylester) were re-
ported to justify this finding.  
Töllner et al., 
2014 
The findings from this study have shown that N-methylation 
completely diminishes the Pgp affinity of barbiturates. 
Mairinger et al., 
2012 
The results obtained from the investigations suggested that, 
phenobarbital potentiates the activity of glutapyrone and so-
dium valproate, thereby significantly minimizing their doses, 
and reducing the risk of side effects when these drugs are ad-
ministered in higher doses and for a longer duration. 




The children who were not administered daily with phenobarbi-
tal had reported a higher incidence of epileptic episodes. How-
ever, these were primarily observed to be febrile seizures. The 
occurrence of pre-seizures and other abnormalities were also 
seen to be relatively high. 
Sakuma et al., 
2020 
Findings from this study have shown that the predisposing fac-
tors in infant subjects were oxygen deprivation, nerve related 
problems, and earlier barbiturate administration. Interestingly, 
in premature neonate extreme apnea was reported to be a pre-




The results from this study had pointed out that prenatal PHB 
affected the anatomical maturation of the hippocampal archi-
tecture. Therefore, administration of PHB in management of 
such conditions is questionable. 
Schizodimos et 
al., 2020 
Thyroidal secretions were observed to be decreased in neo-
nates administered with phenobarbitone. In addition, neural de-
ficiencies and structural irregularities in neuronal tissues were 
seen in phenobarbitone use. Neuronal studies further revealed 
decreased sensitivity of DBA in subjects who were adminis-
tered with phenobarbitone. The authors also elaborated on the 
existence of interactions between several genotypes as the 
nervous system developed.  
Hadjihambi et 
al., 2020 
Administration of barbiturate drugs in infants for seizure pre-
ventive measures is not often recommended for normal clinical 
procedures, as incidences of death were reported in several 
Young et al., 
2016 
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studies. Lack of suitable supporting studies have made it further 
challenging.  
Brain tumor Two separate groups were studied. The findings suggest no 
drastic changes or differences among the study cohorts, in 
terms of adverse events. In addition, there were no fatalities 
due to BCT. The conclusions suggested efficient monitoring of 
refractory intracranial hypertension (RICH) after surgery.  
Ryu et al., 2019 
 From the findings of the study, it was evident that the strategy 
was focused to improve extreme deficiency of potassium in the 
blood. The findings also were strategized to prevent paroxys-
mal, fatal, rebounding potassium levels in the blood. Inspite of 
such efforts, the subjects who received the Barbiturate coma 
therapy (BCT) still reported and presented with having low 
grade hyperkalaemia. 
Tat et al., 2017 
 Two major groups, namely the intervention group and the con-
trol group were studied. The findings suggested no significant 
differences in controlling epileptic episodes in the brain tumor 
subjects. Subjects who were on antiepileptic medications car-
ried a higher risk of developing complications. These findings 
however may not be applied for drugs other than phenytoin, 
phenobarbital, and divalproex sodium. 
Tremont-Lukats 
et al., 2008 
 Administration of phenobarbital may result in grave anatomical 
alterations in the architecture of the microtubules. Phenobarbi-
tal is also known to cause the destabilization of c-Jun, Akt and 
ERK proteins during the signaling process. To conclude, the 
observations reveal that the migratory and proliferation mecha-
nisms of pentobarbital are arrested due to the disturbances in 
the microtubule function. The suggested mechanisms involve 
the ERK, c-Jun MAPK and PI3K/Akt pathways. 
Xie et al., 2009 
 The study reports that subjects with brain tumors may not ben-
efit from seizure preventive medications if they did not have a 
past-history of convulsions.  




The study reports that, compared to barbiturates, propofol can 
control RSE and shorten ATIPT in a more competent and ap-
propriate manner. Moreover, the study also suggests that the 
drug does not increase the occurrence of hypotension and 
CFR. 
 
Zhang et al., 
2019 
 The study reported that the recurrence rate for late seizures 
was 13.6 % after having a strong influence with antiseizure 
drugs (ASD) in subjects having new onset status epilepticus 
(NOSE). The study also highlights that the probability of the 
convulsions to reoccur may be high in subjects with refractory 
status epilepticus (RSE) who were on barbiturate therapy. Fur-





 The study reports that VPA (valproate) and PB (phenobarbital) 
were more effective than PHT (phenytoin/fosphenytoin) in sub-
jects with SE (status epilepticus). However, PHT is not proven 
to be effective and is also expensive, which is a drawback when 




 The authors show that moderate-dose parenteral PB (pheno-
barbital) was efficient in attaining considerable seizure man-
agement in non-comatose refractory SE patients. None of the 
patients required ventilatory support. The authors conclude that 
PB dosages beneath those in recent guidelines may be suffi-
cient to stop SE without clinically significant cardiopulmonary 
complications. 
Hocker et al., 
2018 
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 The study reported that PB (phenobarbital) at a dose greater 
than 100 µg/ml was found to be beneficial in adult subjects with 
refractory status epileptic (RSE). Furthermore, therapeutic 
plasma exchange has no effect on the amount of PB found in 
plasma. 





The findings from this study indicate that barbiturates, when 
used in a modern NICU (neurointensive care unit), serves as a 
promising strategy to safely reduce intracranial pressure with-
out causing any extreme adverse effects in younger population 
who suffer from refractory intracranial hypertension (RICH) with 
potential long-term benefits. 
Velle et al., 
2019 
 The observations from this study discuss about the significance 
of hypothermia which was caused by pentobarbital. The find-
ings suggest that a combination of barbiturates with other suit-
able prescribed medication would be beneficial in post-opera-
tive refractory intracranial hypertension. This may also be ef-
fective in overcoming the effects of intraoperative cranial in-
flammation in younger patients with brain injury.  
Mansour et al., 
2013 
 The study reports that, unlike short-acting barbiturates, drugs 
like phenobarbital which have sustained pharmacological ac-
tion may not be an appropriate choice of drugs when it comes 
to surgical induction. Phenobarbital may be helpful to decrease 
the metabolism in the brain and thereby decrease the intracra-
nial pressure. However, phenobarbital causes several unto-
ward actions, the principal one being hypotension. This may tilt 
the balance negatively wiping off the beneficial effects.  
Lewis and 
Adams, 2021 
 According to Shein et al. intracranial pressure was observed to 
be lowered after phenobarbital administration. However, hyper-
tonic saline was seen to have more merit as the first-line drug 
for treating intracranial hypertension, as it regulated the sym-
pathetic cerebral hemodynamics and produced the fastest res-
olution of intracranial hypertension. 
Shein et al., 
2016 
 In this study, the authors showed that intracranial pressure fell 
after administration of HTS (hypertonic saline), mannitol, or 
barbiturates, which showed continued improvement after 2 
hours. 
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